Head-To-Head Contrast: China Biologic Products (CBPO) versus Fate Therapeutics (NASDAQ:FATE)

China Biologic Products (NASDAQ: CBPO) and Fate Therapeutics (NASDAQ:FATE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership.

Institutional and Insider Ownership

53.9% of China Biologic Products shares are held by institutional investors. Comparatively, 74.6% of Fate Therapeutics shares are held by institutional investors. 2.7% of China Biologic Products shares are held by insiders. Comparatively, 9.9% of Fate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.



Analyst Ratings

This is a summary of recent ratings for China Biologic Products and Fate Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China Biologic Products 0 1 1 0 2.50
Fate Therapeutics 0 2 5 1 2.88

China Biologic Products presently has a consensus price target of $101.00, suggesting a potential upside of 1.30%. Fate Therapeutics has a consensus price target of $16.17, suggesting a potential upside of 33.83%. Given Fate Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Fate Therapeutics is more favorable than China Biologic Products.

Valuation & Earnings

This table compares China Biologic Products and Fate Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
China Biologic Products $370.41 million 8.92 $67.94 million $4.95 20.14
Fate Therapeutics $4.11 million 155.36 -$42.95 million ($1.02) -11.84

China Biologic Products has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than China Biologic Products, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

China Biologic Products has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.

Profitability

This table compares China Biologic Products and Fate Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
China Biologic Products 17.76% 17.29% 14.89%
Fate Therapeutics -1,143.99% -77.27% -54.40%

Summary

Fate Therapeutics beats China Biologic Products on 8 of the 15 factors compared between the two stocks.

China Biologic Products Company Profile

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing immune globulin intravenous; human antithrombin III; Caprylate/Chromatography Purified and 20 nm virus filtration; human coagulation factor IX; human cytomegalovirus immunoglobulin; and human fibrin sealant products. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; ToleraCyte for the treatment of autoimmune and inflammatory diseases; and FT300 iPSC-derived myeloid derived suppressor cell product candidate for the treatment of autoimmune diseases. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf engineered T-cell product candidates; a research collaboration partnership with the University of California San Diego to develop off-the-shelf chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. It also has a strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply